Integer Holdings Corporation
ITGR · NYSE
Company research
Integer Holdings Corporation (NYSE: ITGR) is one of the largest medical device contract development and manufacturing organizations (CDMO) in the world, headquartered in Plano, Texas, and founded in 1970 by Wilson Greatbatch. Operating as a pure-play medical technology company following the 2024 divestiture of its Non-Medical Electrochem business, Integer serves as a critical outsourced manufacturing partner for major OEMs such as Medtronic, Abbott, and Boston Scientific, delivering precision-engineered components and finished devices across cardiac rhythm management, neuromodulation, and cardio and vascular markets. The company's diverse product portfolio spans implantable pacemakers, defibrillators, spinal cord stimulators, catheters, guidewires, implantable batteries, and advanced surgical instruments, all manufactured across global facilities in the United States, Puerto Rico, Costa Rica, and other international regions. Under the leadership of CEO Payman Khales, appointed in October 2025, Integer operates with a market capitalization of approximately $3.2 billion and approximately 11,000 full-time employees, maintaining its position as the only publicly traded pure-play medical device CDMO.
Research reports
StockStory’s underperform‑rated Q1 CY2026 research report highlights flat reported revenue versus the prior year, downward revisions to full‑year revenue, EPS, and EBITDA guidance, margin and free‑cash‑flow compression, and argues that Integer’s modest scale, mediocre ROIC, and slowing demand make it a relatively low‑quality medical device CDMO despite prior EPS growth.
Lubin Investment · June 26, 2026Should you buy Integer Holdings stock? Our full analysis.Lubin Investment’s quantitative fundamental report scores Integer 5/10 on a ten‑factor Buffett/Mauboussin/Damodaran‑based quality framework and notes a high 40.8× P/FCF multiple, concluding that the stock is of medium quality with separate judgment required on valuation and no explicit buy or sell call.
Yahoo Finance · June 7, 2026Assessing Integer Holdings (ITGR) Valuation After Recent Share Price MomentumThis article reviews ITGR’s recent share price momentum, compares the current price to intrinsic value models and analyst targets, finds the stock modestly undervalued relative to consensus fair value, and discusses growth drivers in cardio and vascular segments alongside risks from revenue timing and OEM concentration.
Yahoo Finance · April 30, 2026Integer Holdings (NYSE:ITGR) Surprises With Q1 CY2026...The Q1 CY2026 review describes how Integer’s revenue and adjusted EPS modestly beat analyst expectations but emphasizes lowered full‑year revenue, EPS, and EBITDA guidance, weaker margins and free‑cash‑flow, and characterizes the quarter as broadly disappointing despite the near‑term beat.
Simply Wall St · March 26, 2026Integer Holdings (NYSE:ITGR) - Stock AnalysisSimply Wall St’s automated equity report states ITGR is trading materially below its estimate of fair value, forecasts ~20% annual EPS growth, and highlights solid revenue and earnings trends while noting leverage and cash‑flow risks; overall it presents the stock as undervalued with attractive earnings growth potential.
Yahoo Finance · February 24, 2026A Look At Integer Holdings (ITGR) Valuation After Strong Q4 Beat, 2026 Profit Outlook And BuybacksThis post analyzes Integer’s strong Q4 2025 beat, 2026 profit outlook, and expanded buybacks, contrasting a discounted‑cash‑flow valuation that implies substantial upside with concerns about dependence on key OEM customers and the timing of an expected FY26 re‑acceleration, leading to a mixed view on whether the market has already priced in growth.
Nasdaq / Motley Fool · February 22, 2026Integer Holdings Lands New $99 Million Stake Even With Stock Down Over 30% Past YearThe Nasdaq/Motley Fool article covers activist fund Irenic Capital’s new ~$99m ITGR stake, describes Integer’s 2025 sales and adjusted EPS growth, outlines management’s 2026 EPS and above‑market organic growth ambitions, and argues that despite a ~38% drawdown, solid fundamentals and activist pressure could help close the gap between business performance and share price.